Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
141,152,375
-
Total 13F shares
-
17,456,279
-
Share change
-
+2,274,483
-
Total reported value
-
$18,997,302
-
Price per share
-
$1.09
-
Number of holders
-
41
-
Value change
-
+$2,482,988
-
Number of buys
-
20
-
Number of sells
-
11
Institutional Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) as of Q4 2025
As of 31 Dec 2025,
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,456,279 shares.
The largest 10 holders included
VANGUARD GROUP INC, Aberdeen Group plc, Two Seas Capital LP, GEODE CAPITAL MANAGEMENT, LLC, PERKINS CAPITAL MANAGEMENT INC, RENAISSANCE TECHNOLOGIES LLC, Lido Advisors, LLC, UBS Group AG, GOLDMAN SACHS GROUP INC, and Bank of New York Mellon Corp.
This page lists
41
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.